Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease

PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance

“…Therefore, various alternatives treatment options have been reported in order to reduce the LDL-C concentration (28)(29)(30)(31)(32). PCSK9 inhibitors have been shown to resulted in a decrease of LDL-C level by up to 70% and have been approved for patients with primary hypercholesterolemia, for patients with statin intolerance and for patients with atherosclerotic cardiovascular disease requiring LDL-C lowering (33,34).…”

High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better

“…In patients with a history of statin-associated adverse effects, PCSK9 inhibitors are well tolerated and very efficacious for LDL-C lowering. [62][63][64][65][66] The major question about PCSK9 inhibitors is their cost-effectiveness. As their cost declines, cost-effectiveness will improve.…”

Ezetimibe and Improving Cardiovascular Outcomes: Current Evidence and Perspectives

“…Nonadherence to statin is not benign and increases the risk of recurrent MI and coronary heart disease events [39]. In a simulation analysis by Canon et al, it was found that the use of ezetimibe is increased by 8% while that of PCSK9 inhibitors by 7% in patients having partial or full statin intolerance (assumed at 10%) [40]. However, PCSK9 inhibitors have cost issues, and it may itself lead to drug discontinuation, so ezetimibe is a first-line option in such patients being an effective lipid-lowering drug with low cost [41].…”